Genesis Therapeutics Secures Financing from NVIDIA; Ottimo Pharma Raises $140 Million for Jankistomig in $100 Billion Market

Genesis Therapeutics has secured additional financing from NVIDIA's venture arm, NVentures, as part of its ongoing efforts to advance its drug development initiatives. Insights from an interview with Genesis founder and CEO Eric Feinberg highlight the strategic plans for utilizing this funding. In a separate development, Ottimo Pharma has successfully completed its Series A funding round, raising over $140 million to accelerate the development of its first-in-class bifunctional medicines targeting oncology. The company plans to file an Investigational New Drug (IND) application for its lead asset, Jankistomig, by late 2025. Ottimo's approach involves a bifunctional antibody that targets PD-1 and VEGFR-2, which is expected to offer a wider therapeutic window compared to existing bispecific drugs. The Series A round was co-led by OrbiMed, Avoro Capital, and Samsara BioCapital, positioning Ottimo to compete in a market projected to reach $100 billion for new cancer therapies.